Sep 9, 2013 by Kanak KantiA Growth Story in Molecular DiagnosticsCepheid is benefiting from the new trends in MDx.
Sep 6, 2013 by Kanak KantiWill You Adopt This Orphan Drug?What are Raptor Pharmaceuticals' opportunities and risks?
Sep 5, 2013 by Kanak KantiThis Biotech Has So Many Reasons to Be LikedIncyte has other good stories besides Jakafi indicated for myelofibrosis.
Aug 29, 2013 by Kanak KantiNew FDA Guidelines Hit This Company HardCan Allergan's Restasis survive the new FDA guidelines?
Aug 28, 2013 by Kanak KantiThe Impact of a Failed Crohn's Disease Trial StudyGlaxoSmithKline lags behind in Crohn’s disease treatment.
Aug 28, 2013 by Kanak KantiAn Edge Emerges in the Race to Treat Muscular DystrophySarepta’s eteplirsen gets advantage from GlaxoSmithKline's failure.
Aug 27, 2013 by Kanak KantiCan This HIV Drug Challenge Gilead's Domination?Can Tivicay be a $5 billion blockbuster?
Aug 27, 2013 by Kanak KantiA Healthcare Stock With an Interesting Value Proposition, Part 2ResMed has captured the global SDB market.
Aug 22, 2013 by Kanak KantiA Solid Orthopedic Implants ManufacturerIntegra is a value story that does not need to look interesting.
Aug 21, 2013 by Kanak KantiThis Small Company Is Winning the War Against Blood CancerIbrutinib is a promising product in blood cancer.
